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Abstract
Methylenetetrahydrofolate reductase and cobalamin-dependent methionine synthase catalyze the penultimate and ultimate
steps in the biosynthesis of methionine in prokaryotes, and are required for the regeneration of the methyl group of methionine in mammals. Defects in either of these enzymes can lead to hyperhomocysteinemia. The sequences of the human
methylenetetrahydrofolate reductase and methionine synthase are now known, and show clear homology with their bacterial analogues. Mutations in both enzymes that are known to occur in humans and to be associated with hyperhomocysteinemia affect residues that are conserved in the bacterial enzymes. Structure/function studies on the bacterial proteins, summarized in this review, are therefore relevant to the function of the human enzymes; in particular studies on the effects of
bacterial mutations analogous to those causing hyperhomocysteinemia in human may shed light on the defects associated
with these mutations.
Keywords: Hyperhomocysteinemia, Polymorphism, Mutations, Cobalamin, Vitamin B12
Abbreviations: AdoMet S-adenosylmethionine; AdoHcy adenosylhomocysteine

Introduction

reaction serves to regenerate the methyl group of methionine.
As indicated in Figure 1, methionine is converted to adenosylmethionine (AdoMet), which serves as a methyl donor in
numerous biosynthetic reactions. The product adenosylhomocysteine (AdoHcy) is then hydrolyzed to form adenosine and
homocysteine. Homocysteine can be reconverted to methionine to provide another methyl group.
Homocysteine is a metabolite at a critical branch point
in 1-carbon metabolism. If the cell is replete with AdoMet,
and the ratio of AdoMet/AdoHcy is high, methylenetetrahydrofolate reductase is inhibited. Under these conditions the
level of methyltetrahydrofolate in the cell is low, and homocysteine is degraded by conversion to cystathionine and
thence to α-ketobutyrate, ammonia, and cysteine. If the ratio
of AdoMet/AdoHcy is low, signalling a need for synthesis of
more AdoMet, methylenetetrahydrofolate reductase inhibition

With the growing interest in the clinical sequelae associated with homocysteinemia, attention has been directed towards studies of the enzymes responsible for the generation
and consumption of homocysteine. As shown in Figure 1,
methylenetetrahydrofolate reductase and methionine synthase
are two such enzymes. Methylenetetrahydrofolate reductase
catalyzes the reduction of methylenetetrahydrofolate to methyltetrahydrofolate. This is the only reaction generating methyltetrahydrofolate in the cell. Methionine synthase catalyzes
a methyl transfer from methyltetrahydrofolate to homocysteine, generating methionine and tetrahydrofolate. In bacteria,
the reaction catalyzed by methionine synthase is the terminal reaction in the de novo biosynthesis of methionine; in humans, for whom methionine is an essential amino acid, this
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Figure 1. Pathways involved in the production of methyltetrahydrofolate and in the regeneration of homocysteine to form methionine.
Enzymes (1) are the methionine adenosyltransferase isozymes, enzymes (2) are AdoMet-dependent methyltransferases, and enzyme
(3) is S-adenosylhomocysteine hydrolase. CH2-H4folate methylenetetrahydrofolate, CH3-H4folate methyltetrahydrofolate, H4folate tetrahydrofolate, AdoHcy adenosylhomocysteine, Pi phosphate anion,
P-Pi pyrophosphate anion.

is relieved, and methyltetrahydrofolate is produced to support
the reaction of methionine synthase. Studies by Kutzbach and
Stokstad [24] demonstrated that methylenetetrahydrofolate
reductase acitvity is allosterically regulated by the AdoMet/
AdoHcy ratio, with AdoMet serving as an inhibitor, and AdoHcy competing with AdoMet for binding to the reductase but
not acting as an inhibitor.
Defects in either methylenetetrahydrofolate reductase [21,
22, 31] or methionine synthase [35, 41] can lead to hyperhomocysteinemia, as can deficiencies in β-cystathionase activity [2].
Severe defects, which lead to greatly elevated blood homocysteine levels, were the first to be identified, but recently we have
realized that defects that lead to mild elevations in blood homocysteine levels are potential long-term risk factors [13, 37, 43].
Such mild defects may be associated with polymorphisms.
During the past 3 years, the nucleotide sequences for the
human cDNAs specifying methylenetetrahydrofolate reductase [16] and methionine synthase [3, 25, 26] have been published. The availability of these sequences permits the identification of mutations that lead to impaired function of these
enzymes, and hence to homocysteinemia. We are thus increasingly able to identify humans at risk for homocysteinemia and its sequelae. Extensive structural and functional
studies of either the mammalian enzymes or their prokaryotic
analogues have been performed, and thus studies can assist in
understanding the defects associated with specific mutations,
and can suggest strategies to ameliorate the symptoms caused
by these mutations.

Methylenetetrahydrofolate reductase
Most of our knowledge about the structure and function
of human methylenetetrahydrofolate reductase derives from
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studies of the closely related porcine enzyme. This enzyme
was initially characterized by Kutzbach and Stokstad, and has
subsequently been extensively studied in our laboratory. Kutzbach and Stokstad [24] partially purified the enzyme from
porcine liver, and showed that it was allosterically regulated
by AdoMet. The enzyme was subsequently purified to homogeneity [5], and shown to contain one equivalent of non-covalently bound FAD per enzyme subunit. The enzyme is a dimer
of identical 77 kDa subunits. Tryptic proteolysis of the native
enzyme was shown to cleave each subunit into two fragments,
an N-terminal 40 kDa fragment and a C-terminal 37 kDa fragment [30]. Tryptic cleavage results in loss of allosteric regulation of enzyme activity by AdoMet, but has no effect on
the catalytic activity of the enzyme, suggesting that the protein may consist of separate catalytic and regulatory regions
[30]. AdoMet was subsequently shown to bind to the Cterminal 37 kDa fragment, implicating this fragment as the regulatory region [38].
The deduced amino acid sequence of the human enzyme
provided further insight into the functional organization of
methylenetetrahydrofolate reductase. The N-terminal region
of the human protein showed extensive similarity with smaller
proteins from enteric bacteria that catalyze the same reaction,
namely the NAD(P)H-dependent reduction of methylenetetrahydrofolate. Since the activity of these enzymes is not allosterically regulated by AdoMet, there was a strong inference
that the N-terminal region of the human enzyme is the catalytic region, and contains determinants for binding of FAD,
NADPH, and methylenetetrahydrofolate. The C-terminal region of the human enzyme shows sequence similarities with
the enzymes from yeast and from the roundworm Caenorhabditis elegans but this region is lacking in the bacterial methylenetetrahydrofolate reductases. The human enzyme contains
an extremely hydrophilic region, Lys-Arg-Arg-Glu- Glu-Asp,
that bridges the catalytic and regulatory regions; cleavage between Lys and Arg residues in this region would divide the
protein into 40 and 34 kDa fragments. The sequence of a peptide in the porcine enzyme that is labeled by irradiation of
methylenetetrahydrofolate reductase in the presence of [3Hmethyl] AdoMet has been determined; a sequence similar to
this peptide is located immediately downstream of the tryptic
cleavage site [16].
Methylenetetrahydrofolate reductase from Escherichia
coli had only previously been characterized in relatively impure preparations [23], and we have developed a method to
purify this enzyme to homogeneity from an overexpressing strain. The purified enzyme is a flavoprotein, and contains non-covalently bound FAD as its cofactor. The enzymebound flavin is reduced by NADH, and much more slowly by
NADPH, and can in turn reduce methylenetetrahydrofolate to
methyltetrahydrofolate.
Rozen and her collaborators [13, 16, 17] have conducted
an extensive search for mutations in the human methylenetetrahydrofolate reductase gene, concentrating especially on
mutations in the N-terminal catalytic region. Several mutations associated with severe deficiency in patients have been
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identified, two such point mutations are Arg157Gln, and
Thr227Met. A polymorphism, Ala222Val, has been shown to
be present in high frequency in humans; in a population of
French Canadians Ala/Val heterozygotes are present at 51%
frequency, and Val/Val homozymgotes at 12% frequency [13].
Humans who are homozygous for the polymorphism have reduced specific activity of methylenetetrahydrofolate reductase in fibroblast extracts, and demonstrate increased susceptibility to heat inactivation of enzyme activity (as assessed by
measuring reductase activity after heating for 5 min at 46°C
and comparing with the activity of controls) [13]. The Val/
Val genotype has subsequently been shown to be associated
with increased risk for neural tube defects [40, 42], and possibly for the develoment of cardiovascular disease [11, 28], although not all studies have found significant correlations [6].
Each of the mutated residues, Arg157, Thr227, and Ala222, is
conserved in the bacterial, yeast, and roundworm sequences
of methylenetetrahydrofolate reductase.
Because the human methylenetetrahydrofolate reductase
has not yet successfully been overexpressed and purified, we
have constructed a homologous mutation to Ala222Val in the
methylenetetrahydrofolate reductase from E. coli, Ala177Val.
This mutation leads to diminished expression of methylenetetrahydrofolate reductase in an overexpressing strain, and the
enzyme activity is rapidly lost during purification. We have
successfully purified the mutant bacterial enzyme to homogeneity by introducing a histidine tag at the C-terminus of the
protein and purifying the enzyme on nickel Sepharose. Our
present studies suggest that the Ala177Val bacterial enzyme is
indeed thermolabile, and that it readily loses its flavin cofactor
on dilution of the protein.
The reduced specific activity of methylenetetrahydrofolate
reductase in humans with the thermolabile mutation [11], and
the resultant elevation in homocysteine in patients with low
folate status [19], may similarly reflect the presence of inactive apo-enzyme in the cells of these individuals.

Methionine synthase
Cobalamin-dependent methionine synthase from E. coli was
initially characterized in the laboratories of Wood, Weissbach,
and Huennekens (reviewed in [29]). These studies established
the participation of the cobalamin (B12) cofactor in the methyl
transfer from methyltetrahydrofolate to homocysteine, and defined the requirements for catalytic turnover. As shown in Figure 2, the cofactor cycles in catalysis between the methylcobalamin form and the cob(I)alamin form. Cob(I)alamin is a strong
reductant, and is occasionally oxidized during catalytic turnover in the presence of oxygen to produce the inactive cob(II)
alamin form of the enzyme. Return of this form of the enzyme
to the catalytic cycle requires a reductive methylation, in which
the methyl group is provided by AdoMet [27]; in E. coli, reduced flavodoxin serves as the electron donor [14]. Thus catalytic turnover in the presence of oxygen requires homocysteine and methyltetrahydrofolate, AdoMet and a reducing system.

in
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Figure 2. Chemistry of the methionine synthase (MS) reaction. In
normal catalysis the B12 prosthetic group cycles a between cob(I)alamin (CO(I)) and methylcobalamin (Co-CH3). Homocysteine demethylates methylcobalamin to generate methionine and cob(I)alamin and
the latter is remethylated by methyltetrahydrofolate (CH3-H4folate)
with formation of tetrahydrofolate. Occasionally, the cob(I)alamin
form of the enzyme becomes oxidized to the inactive cob(II)alamin
form of the enzyme. Return of this form of the enzyme to the catalytic cycle requires a reductive methylation. In E. coli, the electron is
supplied by reduced flavodoxin; the electron donor in mammals has
not yet been identified. AdoMet supplies the methyl group for reductive activation.

The E. coli methionine synthase was first cloned, overexpressed and sequenced in 1989–1990 [1, 32, 33]. As noted
above, the sequence of the human methionine synthase has
been simultaneously determined in three laboratories this year
[3, 25, 26]. The human enzyme shows 58% identity with methionine synthase from E. coli [3]. These two sequences, as
well as sequences from the roundworm Caenorhabditis elegans [39], and the prokaryotes Hemophilus influenzae [12],
Mycobacterium leprae [36], and Synechocystis sp. strain
PCC6803 [20], are aligned in Figure 3. Given the high degree of conservation of amino acid residues throughout the
proteins, the enzymes from these organisms are likely to have
very similar properties and structures. Thus the large body of
information available for the E. coli enzyme is likely to be relevant to the human enzyme.
The porcine methionine synthase has been purified to homogeneity [4] and shown to be similar in size and properties to the enzyme from E. coli. The one respect in which the
mammalian enzymes clearly differ from the bacterial proteins
is in the nature of the biological reducing system. Mammals
lack flavodoxin, necessary for reductive reactivation in E.
coli; the proteins responsible for reductive activation in mammals have not yet been identified.
Our recent studies on the bacterial enzyme have shown it
to be a modular protein, consisting of four regions that are
designated in Figure 3. The N-terminal module (residues
1–353 in the E. coli sequence) is responsible for binding and
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Figure 3. Aligment of the methionine synthase sequence from Homo
sapiens [3, 25, 26] with the sequence from the E. coli metH gene
[1, 10, 33], and homologous sequences from the roundworm Caenorhabditis elegans [39], and the prokaryotes Hemophilus influenzae [12]. Mycobacterium leprae [36], and Synechocystis sp. strain
PCC6803 [20]. Identical residues are shown in bold. The Hemophilus sequence appears to lack most of the N-terminal portion of the
sequence of the other genes, perhaps because it was obtained by
shotgun cloning of the entire genome.

activation of homocysteine (Goulding and Matthews, unpublished data) and shows sequence similarity with human betaine-homocysteine methyltransferase [15]. The next module,
comprising residues 354–649, is involved in the binding and
activation of methyltetrahydrofolate. This module shows sequence similarities with a methyltransferase from Clostridium thermoaceticum that catalyzes methyl transfer from methyltetrahydrofolate to a separate corrinoid iron/sulfur protein
[34]. The third module of the bacterial enzyme, comprising
residues 650–896, contains the determinants for binding the
cobalamin cofactor [1, 8, 34], and presents the cofactor to the
other three modules. A high resolution X-ray structure of this
module has been determined [8]. The fourth and last module,
containing residues 897–1227, binds AdoMet and is required
for reductive activation of methionine synthase [9]. An X-ray
structure of this module, with AdoMet bound, has recently
been determined [7].
Thus, as mutations and polymorphisms of human methionine synthase are identified, we may be able to guess at their
probable phenotypes from their location in the sequence. One
such mutation, Pro1137Leu, is associated with severe disease
in humans [18]. This mutation is located in the activation module of methionine synthase, adjacent the bound AdoMet. This
mutation has a very interesting phenotype; it is active when assayed using a chemical reducing system, but shows very low
activity when assayed with the biological reducing system
[18]. Thus this mutation in the activation domain of methionine synthase appears to have altered the interaction of human
methionine synthase with its biological reducing agent.
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Analysis of other mutations and polymorphisms may not
only tell us whether methionine synthase mutations are independent risk factors for neural-tube defects and/or cardiovascular disease, but may also tell us much about the role of the
methionine synthase protein in catalyzing methyl transfer.
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